Promethera Biosciences Archives

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

December 17, 2019 - 2 minutesmins - By Jonathan Smith

promethera liver failure stem cell therapy

News and Trends 15 Apr 2019

First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials

A stem cell therapy developed by the Belgian company Promethera has improved symptoms, such as jaundice, in patients with acute liver failure, a condition with no effective treatments. A phase I/IIa trial of the therapy recruited 19 patients with chronic liver disease. Of these,12 patients had developed acute-on-chronic liver failure, a life-threatening syndrome where the […]

April 15, 2019 - 2 minutesmins - By Jonathan Smith

In Depth 11 Jul 2017

Regenerating the Body With Stem Cells – Hype or Hope?

When the Japanese researcher Shinya Yamanaka managed to reprogram adult cells into an embryonic-like state to yield induced pluripotent stem cells (iPSCs), this was supposed to herald a revolution in regenerative medicine. But 10 years after their discovery, a therapeutic breakthrough is still outstanding. “The overall stem cell therapy field has failed today to show […]

July 11, 2017 - 9 minutesmins - By Melanie De Almeida

liver anatomy organs Sebastian Kaulitzki fi

News and Trends 21 Nov 2016

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company’s seemingly diverse interests and future direction. Promethera is the new kid on Belgium’s biotech block in Louvain-la-Neuve, and it’s hatching plans to make a splash with an IPO next spring. […]

November 21, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 15 Sep 2015

Louvain-la-Neuve: A Belgian temple for success in cell therapy

Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist. The financing round, led by New […]

September 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Nov 2014

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, raised 25,33 million euros. The major innovation of Promethera HepaStem is based on Heterologous Human Adult Liver Progenitor Cells (HHALPC). It is a potential to treat a wide variety of congenital […]

November 25, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 25 Oct 2014

Belgian Promethera received approval to start World first Phase IIb/III stem-cell based urea cycle disorders treatment

Promethera is a promising Belgian Biotechnology company developing stem-cell based treatment against liver diseases. It was created in 2009, counts 44 employees and has raised €39M. The company now moves to another level by starting its own Phase IIb/III to treat paediatric patients with urea cycle disorders. It is the first company in the World […]

October 25, 2014 - 1 minutemin - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promethera Biosciences

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

First Stem Cell Therapy for Liver Failure Shows Promise in First Human Trials

Regenerating the Body With Stem Cells – Hype or Hope?

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Infographic: The Anatomy of European Biotech

Louvain-la-Neuve: A Belgian temple for success in cell therapy

Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Belgian Promethera received approval to start World first Phase IIb/III stem-cell based urea cycle disorders treatment

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!